Houston Methodist is once again the top hospital in Texas. Photo via Houston Methodist

U.S. News & World Report has released its 2025 rankings of the best hospitals in Texas, and they prove that Houston is in good hands.

The esteemed Houston Methodist Hospital was rated the No. 1 best hospital in Texas for the 14th consecutive year, and the No. 1 hospital in the metro area. Eleven more Houston-area hospitals earned spots among the statewide top 35.

U.S. News annually evaluates 581 Texas hospitals to determine which meet the publication's rigorous standards and offer the best care for patients. Hospitals are also ranked among 15 specialties, including cancer, cardiology, heart and vascular surgery, obstetrics and gynecology, orthopedics, psychiatry, rehabilitation, diabetes and endocrinology, and more.

Houston Methodist also appeared on U.S. News' prestigious list of Honor Roll hospitals, consisting of 20 medical centers that are deemed the "best of the best" hospitals in the nation. No other Texas hospitals made the list, further proving that Houston Methodist takes exceptional care of its patients.

"This is a tremendous achievement for our physicians and employees who dedicate themselves every day to our patients," said Marc Boom, M.D., president and CEO of Houston Methodist, in a press release. "We take pride in these national recognitions but more importantly, these accolades reflect our unparalleled commitment to keeping our patients at the center of everything we do."

Houston Methodist earned several top-20 rankings across 11 of the 15 total specialties nationwide. It also earned national recognition for having the 7th best gastroenterology/GI surgery program, the 8th best pulmonology and lung surgery programs, and the 10th best diabetes and endocrinology programs in the country.

Elsewhere in Houston, The University of Texas MD Anderson Cancer Center ranked as the No. 1 best cancer hospital in the nation for the 11th year in a row.

"We are honored to again be ranked as the nation’s top hospital for cancer care – a recognition that reaffirms our commitment to our shared mission to end cancer," said MD Anderson president Peter WT Pisters, M.D., in a release. "We are grateful to every one of our teammates, trainees, students, donors, volunteers, advocates and patients, whose unwavering dedication make it possible for MD Anderson to deliver outstanding patient care."

Other top-performing Houston-area hospitals that ranked among the best in Texas include:

  • No. 4 – Baylor St. Luke's Medical Center
  • No. 5 – Memorial Hermann Greater Heights Hospital
  • No. 6 – Memorial Hermann Hospital
  • No. 8 – Houston Methodist Sugar Land Hospital
  • No. 9 – Houston Methodist Willowbrook Hospital
  • No. 12 – Houston Methodist The Woodlands Hospital
  • No. 13 – Memorial Hermann Memorial City Medical Center (tied with Baylor Scott and White All Saints Medical Center - Fort Worth)
  • No. 21 – Houston Methdodist Baytown Hospital (tied with Methodist Hospital - Stone Oak in San Antonio and Texas Health Harris Methodist Hospital Fort Worth)
  • No. 25 – HCA Houston Healthcare Clear Lake in Webster (tied with St. Luke's Health - The Woodlands Hospital, Baylor Scott and White Medical Center - Round Rock-Lakeway, and Texas Health Presbyterian Hospital Plano)
  • No. 29 – University of Texas Medical Branch in Galveston (tied with Medical City Plano)
---

This article originally appeared on CultureMap.com.

The merger that would have created the largest hospital system in Texas has been called off. Photo via memorialhermann.org

Major Texas hospital merger between Memorial Hermann and Baylor Scott & White called off

Discharged

Two Texas hospitals that were headed for union have called off their engagement plans, according to a joint statement. Dallas-based Baylor Scott and White and Houston-based Memorial Hermann announced in October that they were on track to combine forces following a letter of intent to merge and create a combined system.

The merger would have created a system with over 68 hospital campuses, 1,100 care delivery sites, almost 14,000 physicians, and serve almost 10 million patients each year, according to the October release. The more formalized agreement was expected this year.

"After months of thoughtful exploration, we have decided to discontinue talks of a merger between our two systems," the February 5 release states. "Ultimately, we have concluded that as strong, successful organizations, we are capable of achieving our visions for the future without merging at this time."

Jim Hinton, current CEO of Baylor Scott and White, was announced to be the system's CEO. Chuck Stokes, president and CEO of Memorial Hermann, was said to serve in the proposed office of the CEO, along with Baylor Scott and White president, Pete McCanna.

"We have a tremendous amount of respect for each other and remain committed to strengthening our communities, advancing the health of Texans and transforming the delivery of care," the release continues. "We will continue to seek opportunities for collaboration as two forward-thinking, mission-driven organizations."

This story will be updated as more information becomes available.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston startup raises $6M to scale home-based healthcare platform

fresh funding

As healthcare systems race to expand care beyond hospitals and into the home, investors are placing bigger bets on the infrastructure needed to make that shift possible.

This month, Rosarium Health announced it has raised $6 million in seed funding led by Kalos Ventures, with participation from ResilienceVC, Rock Health Capital, Symphonic Capital, Black Tech Nations Ventures and others.

The investment will help the Houston-based startup continue to build its platform, which features a national network of 800-plus clinicians and 3,000-plus contractors to coordinate home accessibility upgrades and modifications for seniors and people living with disabilities.

For founder and CEO Cameron Carter, the company’s mission grew out of firsthand caregiving experiences.

“From my own personal caregiving experiences, I realized that the benefits exist on paper, but not in reality,” Carter said in a news release. “Families are being left to figure out the paperwork and installations all on their own, which shouldn’t be how this works.”

While Medicare Advantage and Medicaid plans have expanded coverage for home-based services and accessibility modifications, the logistics behind delivering those services often remain fragmented.

Rosarium’s platform coordinates the entire process, from clinical assessments and referrals to contractor management, documentation, reimbursement and installation.

“A clinician can document that a home isn’t safe and a plan can approve a benefit, but there’s no one that’s responsible for making sure the work actually gets done,” Carter says. “We built the missing piece.”

The company was founded in 2021 as Rose Health and was a 2023 participant in the Texas Medical Center’s Accelerator for HealthTech program. It has scaled quickly, building a network of more than 800 clinicians and 3,000 contractors across 34 states.

Rosarium is currently in-network for 1.2 million Medicare and Medicaid lives, with projected coverage expected to reach nearly 4 million by the end of the year, according to the release.

“We’re excited to back Cameron because he and the team at Rosarium are building the infrastructure healthcare needs right now to make the home a safe and comfortable place of care,” Kate Ballinger, investor at Kalos Ventures, added in the release.

As part of the recent investment, Ballinger will join Rosarium’s board of directors.

With eyes on the future, Rosarium plans to grow its partnerships with Medicaid and Medicare Advantage plans, including CalViva and Community Health Plan of Imperial Valley, strengthening its presence in California while expanding access to underserved communities.

Additionally, Carter predicts that home-based healthcare will be part of a broader transformation happening across the industry.

“There’s a growing recognition that health outcomes are shaped by what happens in the home,” he said in the release. “The future of healthcare isn’t just treating people after something goes wrong. It’s creating environments that help prevent those problems in the first place.”

Houston business mogul Tilman Fertitta acquires Caesars in $17.6B deal

Money Moves

Houston billionaire Tilman Fertitta may currently be serving as America’s ambassador to Italy, but his company is as busy as ever. Fresh off its move to revive the Houston Comets WNBA franchise, his company, Fertitta Entertainment, has announced a $17.6 billion deal to acquire Caesars Entertainment, Inc.

Speculation about the deal has been circulating since at least March, according to various media reports. The deal combines Fertitta’s well-known Golden Nugget casino brand with all of the properties in the Caesars’ portfolio, including Las Vegas hotels Caesars Palace, Harrah's, Paris Las Vegas, Planet Hollywood, Horseshoe, The LINQ Hotel, Flamingo, and The Cromwell.

Overall, the combined company will include 60 domestic casino resorts and gaming facilities; online gaming including sports betting, iCasino, and Caesar’s online poker platform; retail sports betting at over 200 third-party locations through the William Hill brand; and over 550 Fertitta Entertainment outlets, including more than 450 Landry's full-service restaurants across America. The companies will combine their loyalty programs, Caesars Rewards, Golden Nugget's 24 Karat Select Club, and Landry's Select Club.

The terms will see Caesars’ shareholders receive $31 per share. Fertitta Entertainment will also acquire approximately $11.9 billion of Caesars' outstanding debt.

The transaction will be financed through a combination of equity contributed by Fertitta Entertainment, assumed Caesars' debt, and new committed debt financing arranged by a group consisting of 10 banks. It is subject to approval by Caesars’ shareholders and government regulators.

Fertitta Entertainment is the Houston-based company behind a diverse array of hospitality businesses, including The Golden Nugget, The Post Oak Hotel, River Oaks District, the Kemah Boardwalk, and Houston’s Downtown Aquarium.

It also operates a number of prominent restaurant brands, including Mastro's Restaurants, Del Frisco's Double Eagle Steakhouse, Morton's The Steakhouse, The Palm, McCormick & Schmick's, Landry's Seafood House, The Oceanaire Seafood Room, and Saltgrass Steak House.

---

This article first appeared on CultureMap.com.

4 Houston-area institutions get $8M for cancer research facilities

fighting cancer

Cancer research capabilities in the Houston area just got an $8 million boost.

On Wednesday, May 20, the Cancer Prevention and Research Institute of Texas (CPRIT) awarded $8 million in grants to institutions in Houston and Bryan for the creation or expansion of so-called “core” cancer research facilities.

“Core facilities provide shared access to advanced technology, equipment, and scientific expertise that may not be available at every institution,” CPRIT says. “These core facilities are vital to not only cancer research but also to the study of diseases beyond cancer.”

Houston-area recipients of these $2 million grants are:

  • A facility at the University of Texas Health Science Center for preclinical support of cancer researchers in Texas to evaluate new safe, effective drugs and drug combinations.
  • The Accelerator for Cancer Therapeutics, operated by Houston’s Texas Medical Center Foundation. The accelerator helps researchers and startups move innovative cancer treatments from the lab to clinical trials.
  • Rice University’s Genetic Design & Engineering Center in Houston. The center enables researchers to collaborate on studies of custom DNA for cancer treatment.
  • A facility at the Texas A&M University System’s Health Science Center in Bryan that aims to speed up the development of cancer therapies.

In addition to those grants, the University of Texas M.D. Anderson Cancer Center, Methodist Hospital Research Institute, Baylor College of Medicine, and Rice University shared $21 million to recruit cancer researchers from other institutions.

The largest of those grants—totalling $4 million—went to M.D. Anderson for the recruitment of renowned cancer researcher Andre Nussenzweig from the National Institutes of Health. His research focuses on how DNA damage and faulty DNA repairs lead to cancer.

Here are the totals for the other CPRIT grants awarded in the Houston area:

  • $12.8 million to Houston-based Indapta Therapeutics for the development of an off-the-shelf therapy that naturally kills cancer cells, combined with an immunity-targeting agent for a type of leukemia.
  • $11.1 million to MD Anderson, including $5 million for a statewide platform to improve long-term health outcomes in adolescents and young adults who survived cancer.
  • $8.4 million to Baylor College of Medicine, including $4.8 million for two training programs for cancer researchers.
  • $6.25 million to UT Health Houston, including $4 million for a biomedical informatics and genomics training program for cancer researchers.
  • $4.4 million to the Texas A&M Health Science Center’s Houston campus, including $2.4 million for a cancer therapeutics training program.
  • $2.75 million to Rice, including $250,000 for a study of ovarian cancer.
  • $2 million to Houston-based March Biosciences for the development of a targeted therapy for treating T-cell lymphoma.
  • $1.15 million to the University of Houston, including $900,000 for a platform for detection of lung cancer.
  • $900,000 to Texas A&M in Bryan to conduct clinical drug trials in rural and underserved communities around the state.
  • $800,000 to Houston- and Israel-based Xerient Pharma for the development of an oral form of a cell-protecting drug called amifostine to protect the upper GI tract from radiation damage during pancreatic cancer treatment.
  • $659,000 to Missouri City-based OmniNano Pharmaceuticals for the development of a two-drug combination to treat the most common form of pancreatic cancer.
  • $250,000 to the University of Texas Medical Branch at Galveston for a novel therapeutic to prevent colitis-related colorectal cancer.